SlideShare a Scribd company logo
1 of 9
Download to read offline
Medication Non-adherence Is Associated With A Broad Range Of Adverse Outcomes In Patients With Coronary Artery Disease   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Disclosure Information DISCLOSURE INFORMATION: This work was supported by an American Heart Association Scientist Development Grant (0535086N)
Background and Objectives ,[object Object],[object Object],[object Object]
Methods ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Baseline characteristics 28-36% Depression 35-45% Diabetes 95% Hyperlipidemia 90% Hypertension 25% Cerebrovascular disease 28% Chronic obstructive pulmonary disease 33-48% Heart failure 42-49% Prior MI 50% Prior PCI 45-50% Prior CABG 20% Current smoker  30% Female gender  65 Age (mean)
Rates of non-adherence Non-adherent patients were younger and more  likely to have COPD and depression n=10,021 n=13,596 n=11,865
Non-adherence to cardioprotective medications is associated with adverse outcomes 0.5 All-cause mortality n=1,889 CV mortality n=372 CV Hospitalization* n=2,008 Coronary Revascularization # n=2,117 B-blockers Statins ACE-inhibitors Hazards Ratio 1.0 2.0 *Hospitalization for AMI or heart failure #PCI or CABG
Non-adherence to H2 antagonists or proton pump inhibitors not associated with adverse outcomes 1.14 (0.97-1.33) All-cause mortality 1.10 (0.78-1.57) CV mortality 1.02 (0.87-1.18) CV hospitalization 1.07 (0.92-1.23) Coronary revascularization Hazard ratio  (95% confidence interval) Outcome
Conclusions ,[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Advances in medical management of HF.. building up the pillars
Advances in medical management of HF.. building up the pillarsAdvances in medical management of HF.. building up the pillars
Advances in medical management of HF.. building up the pillarsPraveen Nagula
 
Heart Failure in Women: More than EF?
Heart Failure in Women: More than EF?Heart Failure in Women: More than EF?
Heart Failure in Women: More than EF?ahvc0858
 
New blood products hemorrhagic stroke apr 14 12
New blood products hemorrhagic stroke apr 14 12New blood products hemorrhagic stroke apr 14 12
New blood products hemorrhagic stroke apr 14 12Ihsaan Peer
 
Cardiovascular Outcome Trials for New Obesity Drugs
Cardiovascular Outcome Trials for New Obesity DrugsCardiovascular Outcome Trials for New Obesity Drugs
Cardiovascular Outcome Trials for New Obesity DrugsEd J. Hendricks, M.D.
 
Cardiovascular Medications in Older Adults
Cardiovascular Medications in Older Adults  Cardiovascular Medications in Older Adults
Cardiovascular Medications in Older Adults PASaskatchewan
 
How to Use Heart Rate Changes to Improve Exercise Test Results How to Use H...
How to Use Heart Rate Changes to Improve Exercise Test Results 	 How to Use H...How to Use Heart Rate Changes to Improve Exercise Test Results 	 How to Use H...
How to Use Heart Rate Changes to Improve Exercise Test Results How to Use H...MedicineAndFamily
 
Jupiter Slides translate
Jupiter Slides translateJupiter Slides translate
Jupiter Slides translateguestef55fa
 
Hope 3 (stat + antihypertensives) TRIAL
Hope 3 (stat + antihypertensives) TRIALHope 3 (stat + antihypertensives) TRIAL
Hope 3 (stat + antihypertensives) TRIALIqbal Dar
 
Atorvastatin:  Statins in CVD management. Is just lipid lowering enough
Atorvastatin:  Statins in CVD management.  Is just lipid lowering enough Atorvastatin:  Statins in CVD management.  Is just lipid lowering enough
Atorvastatin:  Statins in CVD management. Is just lipid lowering enough Dr Vivek Baliga
 
Statins and diabetes
Statins and diabetesStatins and diabetes
Statins and diabetestgraphos
 
JUPITER (Justification for the Use of Statins in Primary Prevention: An Inter...
JUPITER (Justification for the Use of Statins in Primary Prevention: An Inter...JUPITER (Justification for the Use of Statins in Primary Prevention: An Inter...
JUPITER (Justification for the Use of Statins in Primary Prevention: An Inter...theheart.org
 
Guidelines and beyond new drug therapy for heart failure with reduced ejectio...
Guidelines and beyond new drug therapy for heart failure with reduced ejectio...Guidelines and beyond new drug therapy for heart failure with reduced ejectio...
Guidelines and beyond new drug therapy for heart failure with reduced ejectio...ahvc0858
 
Old vs new targets april 2015
Old vs new targets april 2015Old vs new targets april 2015
Old vs new targets april 2015Henry Tran
 
Early Treatment of Atrial Fibrillation (AF) - By Dr Pipin Kojodjojo
Early Treatment of Atrial Fibrillation (AF) - By Dr Pipin KojodjojoEarly Treatment of Atrial Fibrillation (AF) - By Dr Pipin Kojodjojo
Early Treatment of Atrial Fibrillation (AF) - By Dr Pipin Kojodjojoahvc0858
 
Role of statin and clopidogrel in atherothrombotic events
Role of statin and clopidogrel in atherothrombotic eventsRole of statin and clopidogrel in atherothrombotic events
Role of statin and clopidogrel in atherothrombotic eventsPraveen Nagula
 

What's hot (20)

Advances in medical management of HF.. building up the pillars
Advances in medical management of HF.. building up the pillarsAdvances in medical management of HF.. building up the pillars
Advances in medical management of HF.. building up the pillars
 
Heart Failure in Women: More than EF?
Heart Failure in Women: More than EF?Heart Failure in Women: More than EF?
Heart Failure in Women: More than EF?
 
journal club- dual-antiplatelets therapy Post AMI
journal club- dual-antiplatelets therapy Post AMIjournal club- dual-antiplatelets therapy Post AMI
journal club- dual-antiplatelets therapy Post AMI
 
New blood products hemorrhagic stroke apr 14 12
New blood products hemorrhagic stroke apr 14 12New blood products hemorrhagic stroke apr 14 12
New blood products hemorrhagic stroke apr 14 12
 
Cardiovascular Outcome Trials for New Obesity Drugs
Cardiovascular Outcome Trials for New Obesity DrugsCardiovascular Outcome Trials for New Obesity Drugs
Cardiovascular Outcome Trials for New Obesity Drugs
 
Cardiovascular Medications in Older Adults
Cardiovascular Medications in Older Adults  Cardiovascular Medications in Older Adults
Cardiovascular Medications in Older Adults
 
Delay in Controlling ldd Cholesterol Among Older Hypertensive Adults 6.1.09
Delay in Controlling ldd Cholesterol Among Older Hypertensive Adults 6.1.09Delay in Controlling ldd Cholesterol Among Older Hypertensive Adults 6.1.09
Delay in Controlling ldd Cholesterol Among Older Hypertensive Adults 6.1.09
 
How to Use Heart Rate Changes to Improve Exercise Test Results How to Use H...
How to Use Heart Rate Changes to Improve Exercise Test Results 	 How to Use H...How to Use Heart Rate Changes to Improve Exercise Test Results 	 How to Use H...
How to Use Heart Rate Changes to Improve Exercise Test Results How to Use H...
 
Jupiter Slides translate
Jupiter Slides translateJupiter Slides translate
Jupiter Slides translate
 
Hope 3 (stat + antihypertensives) TRIAL
Hope 3 (stat + antihypertensives) TRIALHope 3 (stat + antihypertensives) TRIAL
Hope 3 (stat + antihypertensives) TRIAL
 
Atorvastatin:  Statins in CVD management. Is just lipid lowering enough
Atorvastatin:  Statins in CVD management.  Is just lipid lowering enough Atorvastatin:  Statins in CVD management.  Is just lipid lowering enough
Atorvastatin:  Statins in CVD management. Is just lipid lowering enough
 
Statins and diabetes
Statins and diabetesStatins and diabetes
Statins and diabetes
 
JUPITER (Justification for the Use of Statins in Primary Prevention: An Inter...
JUPITER (Justification for the Use of Statins in Primary Prevention: An Inter...JUPITER (Justification for the Use of Statins in Primary Prevention: An Inter...
JUPITER (Justification for the Use of Statins in Primary Prevention: An Inter...
 
Guidelines and beyond new drug therapy for heart failure with reduced ejectio...
Guidelines and beyond new drug therapy for heart failure with reduced ejectio...Guidelines and beyond new drug therapy for heart failure with reduced ejectio...
Guidelines and beyond new drug therapy for heart failure with reduced ejectio...
 
Old vs new targets april 2015
Old vs new targets april 2015Old vs new targets april 2015
Old vs new targets april 2015
 
CV journal Club
CV journal ClubCV journal Club
CV journal Club
 
Statins-cornerstone in lipid management
Statins-cornerstone in lipid managementStatins-cornerstone in lipid management
Statins-cornerstone in lipid management
 
Early Treatment of Atrial Fibrillation (AF) - By Dr Pipin Kojodjojo
Early Treatment of Atrial Fibrillation (AF) - By Dr Pipin KojodjojoEarly Treatment of Atrial Fibrillation (AF) - By Dr Pipin Kojodjojo
Early Treatment of Atrial Fibrillation (AF) - By Dr Pipin Kojodjojo
 
Rivaroxaban
RivaroxabanRivaroxaban
Rivaroxaban
 
Role of statin and clopidogrel in atherothrombotic events
Role of statin and clopidogrel in atherothrombotic eventsRole of statin and clopidogrel in atherothrombotic events
Role of statin and clopidogrel in atherothrombotic events
 

Viewers also liked

Medication Adherence via Gamification
Medication Adherence via GamificationMedication Adherence via Gamification
Medication Adherence via GamificationMichael Berliner
 
Tools For Improving Adherence to Treatment in Diabetes
Tools For Improving Adherence to Treatment in Diabetes Tools For Improving Adherence to Treatment in Diabetes
Tools For Improving Adherence to Treatment in Diabetes Iris Thiele Isip-Tan
 
034 everybody has atherosclerosis
034 everybody has atherosclerosis034 everybody has atherosclerosis
034 everybody has atherosclerosisSHAPE Society
 
104 new advances in thermography
104 new advances in thermography104 new advances in thermography
104 new advances in thermographySHAPE Society
 
065 association for eradication of heart attack
065 association for eradication of heart attack065 association for eradication of heart attack
065 association for eradication of heart attackSHAPE Society
 
249 the most cost effective therapy
249 the most cost effective therapy249 the most cost effective therapy
249 the most cost effective therapySHAPE Society
 
253 endothelial dysfunction
253 endothelial dysfunction253 endothelial dysfunction
253 endothelial dysfunctionSHAPE Society
 
117 mr images of human carotid arteries
117 mr images of human carotid arteries117 mr images of human carotid arteries
117 mr images of human carotid arteriesSHAPE Society
 
134 mr contrast agents for vulnerable plaque imaging
134 mr contrast agents for vulnerable plaque imaging134 mr contrast agents for vulnerable plaque imaging
134 mr contrast agents for vulnerable plaque imagingSHAPE Society
 
230 plaque crp or myocardial crp
230 plaque crp or myocardial crp230 plaque crp or myocardial crp
230 plaque crp or myocardial crpSHAPE Society
 
219 coronary autoregulation in vivo
219 coronary autoregulation in vivo219 coronary autoregulation in vivo
219 coronary autoregulation in vivoSHAPE Society
 
086 unstable angina, lad stenosis
086 unstable angina, lad stenosis086 unstable angina, lad stenosis
086 unstable angina, lad stenosisSHAPE Society
 
3rd vulnerable plaque rumberger 3 16-02 3
3rd vulnerable plaque rumberger 3 16-02 33rd vulnerable plaque rumberger 3 16-02 3
3rd vulnerable plaque rumberger 3 16-02 3SHAPE Society
 
167 plaque p h heterogeneity in physiological media
167 plaque p h heterogeneity in physiological media167 plaque p h heterogeneity in physiological media
167 plaque p h heterogeneity in physiological mediaSHAPE Society
 
152 spio photographs
152 spio photographs152 spio photographs
152 spio photographsSHAPE Society
 
160 5th vulnerable plaque symposium
160 5th vulnerable plaque symposium160 5th vulnerable plaque symposium
160 5th vulnerable plaque symposiumSHAPE Society
 

Viewers also liked (20)

Hypertension
HypertensionHypertension
Hypertension
 
Medication Adherence via Gamification
Medication Adherence via GamificationMedication Adherence via Gamification
Medication Adherence via Gamification
 
Adherence to Medication_v3
Adherence to Medication_v3Adherence to Medication_v3
Adherence to Medication_v3
 
Tools For Improving Adherence to Treatment in Diabetes
Tools For Improving Adherence to Treatment in Diabetes Tools For Improving Adherence to Treatment in Diabetes
Tools For Improving Adherence to Treatment in Diabetes
 
163 infra redx
163 infra redx163 infra redx
163 infra redx
 
034 everybody has atherosclerosis
034 everybody has atherosclerosis034 everybody has atherosclerosis
034 everybody has atherosclerosis
 
104 new advances in thermography
104 new advances in thermography104 new advances in thermography
104 new advances in thermography
 
065 association for eradication of heart attack
065 association for eradication of heart attack065 association for eradication of heart attack
065 association for eradication of heart attack
 
249 the most cost effective therapy
249 the most cost effective therapy249 the most cost effective therapy
249 the most cost effective therapy
 
253 endothelial dysfunction
253 endothelial dysfunction253 endothelial dysfunction
253 endothelial dysfunction
 
117 mr images of human carotid arteries
117 mr images of human carotid arteries117 mr images of human carotid arteries
117 mr images of human carotid arteries
 
134 mr contrast agents for vulnerable plaque imaging
134 mr contrast agents for vulnerable plaque imaging134 mr contrast agents for vulnerable plaque imaging
134 mr contrast agents for vulnerable plaque imaging
 
230 plaque crp or myocardial crp
230 plaque crp or myocardial crp230 plaque crp or myocardial crp
230 plaque crp or myocardial crp
 
219 coronary autoregulation in vivo
219 coronary autoregulation in vivo219 coronary autoregulation in vivo
219 coronary autoregulation in vivo
 
086 unstable angina, lad stenosis
086 unstable angina, lad stenosis086 unstable angina, lad stenosis
086 unstable angina, lad stenosis
 
3rd vulnerable plaque rumberger 3 16-02 3
3rd vulnerable plaque rumberger 3 16-02 33rd vulnerable plaque rumberger 3 16-02 3
3rd vulnerable plaque rumberger 3 16-02 3
 
167 plaque p h heterogeneity in physiological media
167 plaque p h heterogeneity in physiological media167 plaque p h heterogeneity in physiological media
167 plaque p h heterogeneity in physiological media
 
152 spio photographs
152 spio photographs152 spio photographs
152 spio photographs
 
160 5th vulnerable plaque symposium
160 5th vulnerable plaque symposium160 5th vulnerable plaque symposium
160 5th vulnerable plaque symposium
 
138 new vp website
138 new vp website138 new vp website
138 new vp website
 

Similar to Medication non-adherence is associated with a broad range of adverse outcomes in patients with coronary artery disease

Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...LupusNY
 
Dyslipidemia -Assessment and management based on evidence
Dyslipidemia -Assessment and management based on evidence  Dyslipidemia -Assessment and management based on evidence
Dyslipidemia -Assessment and management based on evidence SYEDRAZA56411
 
CARDIO ONCOLOGY
CARDIO ONCOLOGYCARDIO ONCOLOGY
CARDIO ONCOLOGYflasco_org
 
ueda2012 do we still need high doses-d.mohammed
ueda2012 do we still need high doses-d.mohammedueda2012 do we still need high doses-d.mohammed
ueda2012 do we still need high doses-d.mohammedueda2015
 
Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...
Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...
Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...hivlifeinfo
 
Newer Approach in management of Angina & CHF: Heart rate modulation and beyond..
Newer Approach in management of Angina & CHF: Heart rate modulation and beyond..Newer Approach in management of Angina & CHF: Heart rate modulation and beyond..
Newer Approach in management of Angina & CHF: Heart rate modulation and beyond..Arindam Pande
 
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...gpartha85
 
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...gpartha85
 
Cv safety of gliptins
Cv safety of gliptinsCv safety of gliptins
Cv safety of gliptinsDrNeerajB
 
Hipertensão Arterial - Slides da JNC7
Hipertensão Arterial - Slides da JNC7Hipertensão Arterial - Slides da JNC7
Hipertensão Arterial - Slides da JNC7semiologia
 
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...Sameer Shete
 
Acute Heart Failure: Current Standards and Evolution of Care.2015
Acute Heart Failure: Current Standards and Evolution of Care.2015Acute Heart Failure: Current Standards and Evolution of Care.2015
Acute Heart Failure: Current Standards and Evolution of Care.2015hivlifeinfo
 
1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf
1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf
1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdfKs doctor
 
International Study of Comparative Health Effectiveness with Medical and Inva...
International Study of Comparative Health Effectiveness with Medical and Inva...International Study of Comparative Health Effectiveness with Medical and Inva...
International Study of Comparative Health Effectiveness with Medical and Inva...Chi Pham
 

Similar to Medication non-adherence is associated with a broad range of adverse outcomes in patients with coronary artery disease (20)

Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
 
2008.02.12 Massie Hyperlipidemia
2008.02.12    Massie   Hyperlipidemia2008.02.12    Massie   Hyperlipidemia
2008.02.12 Massie Hyperlipidemia
 
Dyslipidemia -Assessment and management based on evidence
Dyslipidemia -Assessment and management based on evidence  Dyslipidemia -Assessment and management based on evidence
Dyslipidemia -Assessment and management based on evidence
 
CARDIO ONCOLOGY
CARDIO ONCOLOGYCARDIO ONCOLOGY
CARDIO ONCOLOGY
 
ARB MI PARADOX-1.pptx
ARB MI PARADOX-1.pptxARB MI PARADOX-1.pptx
ARB MI PARADOX-1.pptx
 
Rosuvastatin
RosuvastatinRosuvastatin
Rosuvastatin
 
ueda2012 do we still need high doses-d.mohammed
ueda2012 do we still need high doses-d.mohammedueda2012 do we still need high doses-d.mohammed
ueda2012 do we still need high doses-d.mohammed
 
Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...
Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...
Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...
 
Newer Approach in management of Angina & CHF: Heart rate modulation and beyond..
Newer Approach in management of Angina & CHF: Heart rate modulation and beyond..Newer Approach in management of Angina & CHF: Heart rate modulation and beyond..
Newer Approach in management of Angina & CHF: Heart rate modulation and beyond..
 
Angina com slideshare
Angina com slideshareAngina com slideshare
Angina com slideshare
 
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
 
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
 
Cv safety of gliptins
Cv safety of gliptinsCv safety of gliptins
Cv safety of gliptins
 
Hipertensão Arterial - Slides da JNC7
Hipertensão Arterial - Slides da JNC7Hipertensão Arterial - Slides da JNC7
Hipertensão Arterial - Slides da JNC7
 
Joint National Committee
Joint National CommitteeJoint National Committee
Joint National Committee
 
Acute Heart Failure
Acute Heart FailureAcute Heart Failure
Acute Heart Failure
 
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
 
Acute Heart Failure: Current Standards and Evolution of Care.2015
Acute Heart Failure: Current Standards and Evolution of Care.2015Acute Heart Failure: Current Standards and Evolution of Care.2015
Acute Heart Failure: Current Standards and Evolution of Care.2015
 
1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf
1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf
1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf
 
International Study of Comparative Health Effectiveness with Medical and Inva...
International Study of Comparative Health Effectiveness with Medical and Inva...International Study of Comparative Health Effectiveness with Medical and Inva...
International Study of Comparative Health Effectiveness with Medical and Inva...
 

More from SHAPE Society

Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stoneSHAPE Society
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 fSHAPE Society
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)SHAPE Society
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)SHAPE Society
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)SHAPE Society
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for printSHAPE Society
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for printSHAPE Society
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermographySHAPE Society
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st centurySHAPE Society
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosisSHAPE Society
 

More from SHAPE Society (20)

Barth imt
Barth imtBarth imt
Barth imt
 
Braunwald
BraunwaldBraunwald
Braunwald
 
Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stone
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 f
 
Acc v porg becker
Acc v porg beckerAcc v porg becker
Acc v porg becker
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)
 
Acc v porg
Acc v porgAcc v porg
Acc v porg
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)
 
Ac cculprit
Ac cculpritAc cculprit
Ac cculprit
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for print
 
Acc booth inventory
Acc booth inventoryAcc booth inventory
Acc booth inventory
 
Acc 04 vuln pt
Acc 04 vuln ptAcc 04 vuln pt
Acc 04 vuln pt
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for print
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermography
 
A20 gene
A20 geneA20 gene
A20 gene
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosis
 
103100
103100103100
103100
 

Recently uploaded

Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)pranavguleria2
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...DUY NGUYEN PHUC
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Ahmad Thanin
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCEShubhadip Ghosh
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, PDr.Shalu Jain
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......anupamdas2143
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptxtusharchokshi1
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...JakeMatthews12
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxTina Purnat
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUKanhu Charan
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxRajendra Dev Bhatt
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsPradnya Wadekar
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfHongBiThi1
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdfHongBiThi1
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKQuick MedTalk
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...Genesis Institute of Pharmacy, Radhanagari.
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfNetHelix
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 

Recently uploaded (20)

Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCE
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, P
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptx
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptx
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractions
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdf
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 

Medication non-adherence is associated with a broad range of adverse outcomes in patients with coronary artery disease

  • 1.
  • 2. Disclosure Information DISCLOSURE INFORMATION: This work was supported by an American Heart Association Scientist Development Grant (0535086N)
  • 3.
  • 4.
  • 5. Baseline characteristics 28-36% Depression 35-45% Diabetes 95% Hyperlipidemia 90% Hypertension 25% Cerebrovascular disease 28% Chronic obstructive pulmonary disease 33-48% Heart failure 42-49% Prior MI 50% Prior PCI 45-50% Prior CABG 20% Current smoker 30% Female gender 65 Age (mean)
  • 6. Rates of non-adherence Non-adherent patients were younger and more likely to have COPD and depression n=10,021 n=13,596 n=11,865
  • 7. Non-adherence to cardioprotective medications is associated with adverse outcomes 0.5 All-cause mortality n=1,889 CV mortality n=372 CV Hospitalization* n=2,008 Coronary Revascularization # n=2,117 B-blockers Statins ACE-inhibitors Hazards Ratio 1.0 2.0 *Hospitalization for AMI or heart failure #PCI or CABG
  • 8. Non-adherence to H2 antagonists or proton pump inhibitors not associated with adverse outcomes 1.14 (0.97-1.33) All-cause mortality 1.10 (0.78-1.57) CV mortality 1.02 (0.87-1.18) CV hospitalization 1.07 (0.92-1.23) Coronary revascularization Hazard ratio (95% confidence interval) Outcome
  • 9.